MoonLake Immunotherapeutics - Class A Ordinary Shares Share · KY61559X1045 · MLTX (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of MoonLake Immunotherapeutics - Class A Ordinary Shares

No Price

01.05.2026 22:14

Current Prices from MoonLake Immunotherapeutics - Class A Ordinary Shares

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	MLTX	USD	01.05.2026 22:14	16,74 USD	0,36 USD +2,20 %
IEX	MLTX	USD	01.05.2026 19:59	16,73 USD	0,35 USD +2,14 %

Company Profile for MoonLake Immunotherapeutics - Class A Ordinary Shares Share

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.